FACS-sorted DCLK1+ RCC cells display enhanced stemness, and the DCLK1-targeted monoclonal antibody inhibits RCC tumorigenesis when delivered systemically in vivo [14]. Here, DCLK1 is linked to renal cell carcinoma.